The addition of brentuximab vedotin to lenalidomide and rituximab improved survival for certain patients with DLBCL. A similar percentage of patients in each arm experienced treatment-emergent ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback